BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 34227261)

  • 1. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.
    Lee EG; Min J; Kang JY; Kim SK; Kim JW; Kim YH; Yoon HK; Lee SH; Kim HW; Kim JS
    BMC Infect Dis; 2020 Jun; 20(1):446. PubMed ID: 32576154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data.
    Li S; Tan Y; Deng Y; Bai G; Huang M; Shang Y; Wang Y; Xue Z; Zhang X; Wang W; Pan J; Pang Y
    J Infect Public Health; 2024 Jan; 17(1):137-142. PubMed ID: 38000314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey.
    Wang G; Jiang G; Jing W; Zong Z; Yu X; Chen S; Li W; Huang H
    J Infect; 2021 Mar; 82(3):371-377. PubMed ID: 33556430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-2015.
    Lee M; Han J; Kim YR; Kwak N; Kim JH; Park O; Shin S; Moon HS; Kim HJ; Jang MJ; Yim JJ
    Int J Tuberc Lung Dis; 2019 Jul; 23(7):850-857. PubMed ID: 31439118
    [No Abstract]   [Full Text] [Related]  

  • 11. Resistance patterns among multidrug-resistant tuberculosis patients in greater metropolitan Mumbai: trends over time.
    Dalal A; Pawaskar A; Das M; Desai R; Prabhudesai P; Chhajed P; Rajan S; Reddy D; Babu S; Jayalakshmi TK; Saranchuk P; Rodrigues C; Isaakidis P
    PLoS One; 2015; 10(1):e0116798. PubMed ID: 25606853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
    Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
    Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Drug Resistant Tuberculosis in Sanatoria of North Korea.
    Jung J; Jegal Y; Ki M; Shin YJ; Kim CT; Shim TS; Sung N
    J Korean Med Sci; 2017 Jul; 32(7):1105-1110. PubMed ID: 28581266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistance pattern of Mycobacterium tuberculosis strains from patients with pulmonary and extrapulmonary tuberculosis during 2006 to 2013 in a Korean tertiary medical center.
    Lee HY; Lee J; Lee YS; Kim MY; Lee HK; Lee YM; Shin JH; Ko Y
    Korean J Intern Med; 2015 May; 30(3):325-34. PubMed ID: 25995663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
    PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
    Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
    Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey.
    Menzies HJ; Moalosi G; Anisimova V; Gammino V; Sentle C; Bachhuber MA; Bile E; Radisowa K; Kachuwaire O; Basotli J; Maribe T; Makombe R; Shepherd J; Kim B; Samandari T; El-Halabi S; Chirenda J; Cain KP
    Int J Tuberc Lung Dis; 2014 Sep; 18(9):1026-33. PubMed ID: 25189548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Serial Multidrug-Resistant Tuberculosis Strains Causing Treatment Failure and Within-Host Evolution by Whole-Genome Sequencing.
    Chen X; He G; Lin S; Wang S; Sun F; Chen J; Zhang W
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33361124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.